Beam Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Beam Therapeutics

28/02/2023 11:58

* Beam Therapeutics Inc  BEAM.OQ  reported a quarterly
adjusted
loss of 54 cents​​ per share for the quarter ended in December.
The mean expectation of fifteen analysts for the quarter was
for a loss of $1.33 per share.
    * Revenue fell 60.8% to $20.04 million from a year ago;
analysts
expected $12.73 million. 
    * Beam Therapeutics Inc's reported EPS for the quarter was a
loss
of 54 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Beam Therapeutics Inc shares had fallen by 0.3% this
quarter.
    * The company reported a quarterly loss of $38.35 million.
    * Wall Street's median 12-month price target for Beam
Therapeutics
Inc is $70.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 11:58 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -1.33          -0.54          Beat
 Sep. 30 2022      -1.31          -1.56          Missed
 Jun. 30 2022      -1.08          -1.02          Beat
 Mar. 31 2022      -1.32          -1.01          Beat